title: Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
abstract: Effective ex vivo purging techniques can decrease the likelihood of infusing bone marrow contaminated with leukemic cells during autologous transplantation. In preliminary studies, OL(1)p53, a 20-mer phosphorothioate oligonucleotide directed against p53 mRNA, decreased the number of acute myelogenous leukemia (AML) cells in vitro, suggesting a possible role for OL(1)p53 in purging bone marrow harvests of leukemia cells. To demonstrate that OL(1)p53 was nontoxic to hematopoietic progenitor cells, normal bone marrow cells were incubated with 10 microM OL(1)p53 for 36 h, and hematopoietic progenitor cell survival was determined by in vitro colony assays. OL(1)p53 had no toxic effect on the growth of either myeloid (CFU-GM) or erythroid (BFU-E) progenitor cells. OL(1)p53 was then used to ex vivo purge bone marrow harvests from nine patients with either AML or myelodysplastic syndrome (MDS). Bone marrow cells were incubated with 10 microM OL(1)p53 for 36 h before transplantation. The median times posttransplantation for the patient to recover an absolute neutrophil count greater than 0.5 x 10(9)/L and a platelet transfusion independence were 30 days and 56 days, respectively. Incubation of bone marrow cells with OL(1)p53 had no detrimental effect on the growth of hematopoietic progenitor cells, and transplantation of autologous bone marrow cells treated with the phosphorothioate oligonucleotide, OL(1)p53, resulted in successful recovery of circulating neutrophils following high-dose therapy in patients with AML or MDS. The data show that OL(1)p53 can be used safely to purge autologous bone marrow harvests from patients with leukemia.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: J D
authors.initials: JD
authors.lastname: Jackson
authors.forename: S R
authors.initials: SR
authors.lastname: Tarantolo
authors.forename: B
authors.initials: B
authors.lastname: O'Kane-Murphy
authors.forename: P L
authors.initials: PL
authors.lastname: Iversen
authors.forename: E
authors.initials: E
authors.lastname: Bayever
authors.forename: S M
authors.initials: SM
authors.lastname: Joshi
authors.forename: J G
authors.initials: JG
authors.lastname: Sharp
authors.forename: J L
authors.initials: JL
authors.lastname: Pierson
authors.forename: P I
authors.initials: PI
authors.lastname: Warkentin
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
mesh_terms: D000328:Adult; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D010865:Pilot Projects; D013873:Thionucleotides; D014182:Transplantation, Autologous
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; C086760:OL(1)p53